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Pterocarpanquinones (1a–e) and the aza-pterocarpanquinone (2) were synthesized through palladium
catalyzed oxyarylation and azaarylation of conjugate oleﬁns, and showed antineoplasic effect on leuke-
mic cell lines (K562 and HL-60) as well as colon cancer (HCT-8), gliobastoma (SF-295) and melanoma
(MDA-MB435) cell lines. Some derivatives were prepared (3–8) and evaluated, allowing establishing
the structural requirements for the antineoplasic activity in each series. Compound 1a showed the best
selectivity index in special for leukemic cells while 2 showed to be more bioselective for HCT-8, SF-295
and MDA-MB435 cells. Pterocarpanquinones 1a and 1c–e, as well as 8 were the most active on amasti-
gote form of Leishmania amazonensis in culture. Compounds 1a, 1c and 8 showed the best selectivity
index.
 2011 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
The pterocarpanquinones of type 1 comprise a new group of
antineoplasic and antiparasite prototypes. The ﬁrst compounds
of this series, bearing oxygenated substituents at the E-ring
(not shown), were designed and synthesized in our laboratory some
years ago.1 These compounds and other further synthesized
derivatives (Fig. 1), showed antineoplasic activity in cultured breast
cancer,1,2 leukemia,3,4 and lung cancer cell lines,4 some among
them presenting MDR phenotype. These pterocarpanquinones also
showed antileishmanial and antimalarial activities on Leishmania
amazonensis and Plasmodium falciparum in culture.2 Moreover, the
mechanism of the antineoplasic action of 1a on chronic myeloid
leukemia was further studied and led to signiﬁcant apoptosis rate
in cells from patients with chronic myeloid leukemia in treatment
in the National Institute of Cancer (INCA) in Rio de Janeiro.5,6 Thesex: +55 21 2523 5938.
osta).
lsevier OA license.cells exhibit multifactorial drug resistance phenotype such as
P-glycoprotein, MRP1 and p53 overexpression.7–11
In addition, 1a and some derivatives showed low toxicity for
PBMC human blood cells3,4 and murine lymphocytes (high
selectivity index).2,3
The compound 1a was also effective by oral route in controlling
lesion development in mice infected with L. amazonensis, without
altering serological markers of toxicity.6,12
In order to further investigate the structural features required
for the antineoplasic and antileishmanial activities in 1a, new com-
pounds were prepared and evaluated on L. amazonensis, promyelo-
cytic leukemia (HL-60) and chronic myeloid leukemia (K562) cell
lines as well as colon cancer (HCT-8), gliobastoma (SF-295) and
melanoma (MDA-MB435) cell lines (Fig. 1).
Since the cleavage of the C–O bound at the D-ring in compounds
type 1 could be involved in the molecular mechanism of action
(reductive bioactivation),4,13–18 we decided to introduce electron
withdrawing groups at the E-ring, such as in 1c–e, that could
stabilize the phenoxide leaving group and facilitate this pathway.
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Figure 1. Compounds studied in this work.
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prepared for comparative purposes. Excepted for 1b and 1e,
these pterocarpanquinones were previously prepared in our
laboratory.4,19
On the other hand, in aza-pterocarpanquinone 2 the oxygen at
the D-ring was replaced by N–Ts group. Due to resonance stabiliza-
tion provided by sulphone group, the C–N bond could also act as a
reasonable leaving group, as the C–O bond in 1a, and thus 2 would
be expected to facilitate the reductive activation pathway.20 Com-
pounds 3 and 4 are the reduced form of 1a and 2, respectively, and
could be eventually oxidized in the targeting cells, generating
these quinones in situ (pro-drugs). Compounds 5 and 6, and 7
and 8, have similar molecular shapes when compared to 1a and
2, respectively, but do not have in their structure the quinone
group and cannot participate in redox cycles, which are in general
associated with the antineoplasic as well as the antiparasitic actionO
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Scheme 1. Synthesis of pterocarpanquinones 1a–e.of quinones.1–4,21–26 Compounds 2–8 are described for the ﬁrst
time in this work.
Once some pterocarpanquinones also presented antiparasitic
activity,2,12 we decided to evaluate the antileishmanial activity of
these compounds on promastigote and amastigote forms of L. ama-
zonensis. Chromenquinone 9, the synthetic precursor of pterocar-
panquinones 1 and aza-pterocarpanquinone 2, was also
evaluated as antineoplasic and antileishmanial.
2. Results and discussion
2.1. Chemistry
As previously described, 1a was prepared by oxyarylation of
chromenquinone 9 with ortho-iodophenol 10a in the presence of
10 mol %of Pd(OAc)2, in acetoneunder reﬂux, usingAg2CO3 as abase
(Scheme 1).4,19 Under the same conditions, oxyarylation of 9 with
ortho-iodophenols 10b–e led to pterocarpanquinones 1b–e in
moderate chemical yield. However, we could not prepare the aza-
pterocarpanquinone 2 by the azaarylation reaction of chromenqui-
none 9 with ortho-iodo-N-tosyl aniline (11). Since the oxyarylation
reaction under the conditions used herein (cationic mechanism)
goes better for electron-rich oleﬁns,18,27–29 we decided to use 12,
obtained by reduction of 9 followed by O-methylation of the result-
ing dihydroquinone, as starting material for the aza-Heck reaction
with 11. Fortunately, azaarylation of oleﬁn 12 with 11 (Scheme 2)
led to the aza-Heck adduct 4 in good yield. Similarly, 3a–c were
obtained by oxyarylation of 12 with 10a,c,d. The oxidation of 3a–c
and 4 using cerium ammonium nitrate (CAN) in acetonitrile and
water30 furnished the target pterocarpanquinones 1a–c and aza-
pterocarpanquinone 2, respectively, in good yields. This pathway is
an alternative to prepare 1a, 1b and 1c.
Finally, 5 and 6 were, respectively, obtained through the oxy-
arylation of oleﬁns 13a and 13b with 10a, in moderate chemical
yields (Scheme 3). When these oleﬁns were allowed to react with
11, the corresponding aza-Heck adducts 7 and 8 were prepared in
good chemical yields (Scheme 3).OMe
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Table 1
Antineoplasic activity of compounds 1–9 and doxorubicin (D⁄). IC50 values in lM
1–9 HL-60 K562 HCT-8 SF-295 MDA-MB435
1a 1.3 1.67 2.6 3.6 2.3
1b 3.5 3.3 10.4 17.7 11.4
1c 4.1 8.0 >13 >13 >13
1d 6.3 3.48 8.3 8.9 17.4
1e 3.0 13.5 6.0 7.4 10.7
3a 17.4 13.5 21.2 22.4 30.8
2 7.4 5.5 0.6 3.9 0.4
4 >51 46.7 >51 >51 >51
5 >112 >112 >112 >112 >112
6 >112 >112 >112 >112 >112
7 6.1 6.4 9.0 31.5 5.0
8 1.0 1.9 3.0 >62.5 0.5
9 0.5 ND 2.8 2.3 1.8
D⁄ 0.04 1.67 0.02 ND 0.96
ND = Not determined.
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The antineoplasic activity of the compounds 1–8 was evaluated
on ﬁve human cell lines: leukemia (HL-60 and K562), colon cancer
(HCT-8), gliobastoma (SF-295) and melanoma (MDA-MB435).
HL-60 cells, from a promyelocytic leukemia, present a low level
of antioxidant defense and are sensible to oxidative stress31 while
K562 cells, from a chronic myeloid leukemia, contain high levels of
intracellular glutathione (GSH) and are resistant to oxidative
stress.31 Cell viability greater than 90% was observed, even after
treatment of these cells with H2O2 100 lM.32 We did not ﬁnd in
the literature data about the phenotype of HCT-8, SF-295 and mel-
anoma MDA-MB435 cell lines. In table 1 are presented the results
obtained.
Pterocarpanquinone 1a showed a potent antineoplasic activity
on all cell lines studied, while the presence of the electron-releas-
ing methoxy group in 1b decreased the potency on HCT-8, SF-295
and MDA-MB435 cell lines but was still potent on the leukemia cell
lines. The same trend was observed in 1c, substituted by the elec-
tron-withdrawing carbomethoxy group. In 1d, bearing the elec-
tron-withdrawing nitro group and in 1e, substituted by oneTable 2
Cytotoxic effect of compounds 1a, 1d, 2, 7 and 8 on PBMC cells activat
1–8 PBMC PBMC/HL-60 PBMC/HCT-8
1a >20 15.4 7.7
1b 7.8 2.22 0.75
1d 8.6 1.36 1.06
1e 6.0 2.0 1.0
2 23.0 3.12 38.5
8 7.2 7.2 2.4
9 <1.4 2.8 0.5electron-withdrawing and one electron-releasing group, the activ-
ity decreases in all cell lines and this trend was more pronounced
on MDA-MB435 cells. These data showed that HCT-8, SF-295 and
MDA-MB435 were more sensitive to the substituent at the E-ring
in compound type 1 than leukemic cells.
Pterocarpanquinone 1a is the most promising compound of this
series and, in addition, it is more easily synthesized than its deriv-
atives. When the quinone group in 1a is reduced, as in 3a, the po-
tency strongly decreased in all cell lines. These results show that 3a
is not oxidized to 1a in those cells under the conditions of our
assays and suggest that quinone group is involved in the molecular
mechanism of action.
Aza-pterocarpanquinone 2was less potent than pterocarpanqui-
none 1a on leukemia cell lines (HL-60 and K562), equipotent in
SF-295, but was more potent on HCT-8 and MDA-MB435 cell lines.
Interestingly, these cellswere themost resistant forpterocarpanqui-
nones1b–e.Wehavepreviouslydemonstrated in the laboratory that
1a could be activated by bioreduction, acting as alkylating agent and
this mechanism could explain the citotoxic effect of this compound
on cell lines resistant to oxidative stress, such as K562.4 Compounds
5 and 6, lacking the quinonemoiety in their structure,were inactive,
which corroborates this interpretation.
When the quinone group in 2 is reduced, as in 4, the potency
also strongly decreased in all cell lines. These results also show that
4 is not oxidized to 2 under the conditions of our assays and sug-
gest that quinone group is also involved in the molecular mecha-
nism of action of 2. Surprisingly, however, except for SF-295, 7
and 8 showed potent antineoplasic effect on the other cell lines
studied, suggesting that these compounds could act through a dif-
ferent mechanism.33,34 We also decided to evaluate the antineopla-
sic effect of quinone 9 and found that this compound was potently
active on the cell lines studied. Doxorubicin was used as a positive
control. LQB-118 (1a), was 30 times less active than doxorubicin in
HL-60, equipotent in K562, 100 times less potent on HCT-8, and
twice more active in MDA-435. Compound 2, on the other hand,
was much less active in leukemic cells but only 3 times less active
in HCT-8, and twice more active in MDA-435. Compounds 8
(excepted for SF-295) and 9 also presented a very favorable
comparison with doxorubicin.
Next, we evaluated the bioselectivity of the more potent com-
pounds by studying the toxic effect on human PMBC cells activated
by mitogen phytohemagglutinin (PHA) (Table 2).
Pterocarpanquinone 1a and aza-pterocarpanquine 2 showed the
best selectivity index among the compounds tested. While 1a was
more bioselective for HL-60 (PBMC/HL-60, 15.4) and K562 (PBMC/
K562, 12.0) cell lines, compound 2 showed the best selectivity in-
dex for the HCT-8 (PBMC/HCT-8, 38.5), SF-295 (PBMC/SF-295,
5.92) and MDA-MB435 (PBMC/MDA-MB435, 57.7) cell lines.
Compound 8 has also shown a good selectivity index for the
MDA-MB435 cell line (PBMC/MDA-MB435, 14.4). TheN-tosyl group
may be important for the cytotoxic activity since the compound 6
was inactive. Unfortunately, chromenquinone 9, the simplest and
easiest to synthesize derivative, showed a potent antineoplasic
activity on all cell lines studied but presented very low selectivity
index.ed by PHA (IC50 in lM). Selectivity index
PBMC/SF-295 PBMC/MDA-MB435 PBMC/K562
5.5 8.7 12.0
0.44 0.68 9.4
0.96 0.49 ND
0.8 0.56 ND
5.92 57.7 4.33
0.11 14.4 ND
0.6 0.78 ND
Table 3
Antileishmanial activity of compounds 1, 2, 8 and pentamidine (P⁄) on promastigote
and amastigote forms of L. amazonensis and toxicity for M J774 cells (IC50 in lM)
1, 2, 8 Promastigote Amastigote MJ774 M J774/amastigote
1a 1.73 1.45 18.5 12.7
1b 2.85 >20 49.5 ND
1c 2.8 0.5 22.5 45
1d 1.07 1.85 12.1 6.5
1e 1.27 1.25 18 14.4
2 15 >20 >100 ND
8 4.85 2.15 23 10.7
P⁄ 2.2 1.5 70 46
ND = Not determined.
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that 1a and 1d (not shown) can be activated by two electrons
reduction of the quinone group, followed by rearrangement of
the resulting hydroquinone 14, leading to a Michael acceptor 15
which was trapped as adduct of thiophenol (16).4 This mechanism
could explain the cytotoxic effect of this compound on cell lines
resistant to oxidative stress, as K562. This cell line overexpresses
NQO1, the enzyme which promotes a two electrons reduction of
quinones, step required to start the mechanism of bioactivation.
In contrast, when 2 was submitted to the same reaction condi-
tions, the expected Michael adduct type 16 (X = NHTs) could not be
detected in the crude product. In fact, the 1H NMR shows the pres-
ence of a complex mixture of products.
Compounds 1a–e, 2 and 8were also evaluated on L. amazonensis
in culture (promastigote and amastigote forms, Table 3). Except for
2, these compounds were potent on promastigote form of the par-
asite. Except for 2 and 1b, these compounds presented potent
antileishmanial effect on macrophages infected with amastigotes,
the form present in the human disease. The selectivity index was
calculated for amastigote form using M J7744 cells (murine
macrophages) as reference and these data are also shown in
Table 3. The best selectivity index for pterocarpanquinones was
obtained for 1a, 1c and 1e.
In contrast with the low potency of the aza-ptarocarpanquinone
2, compound 8 presented good antiamastigote and antipromasti-
gote activity and good selectivity index (10.7). These results
suggest that different mechanism of action may be contributing
for the observed effects.
3. Conclusions
New bioactive pterocarpanquinones, an aza-pterocarpanqui-
none and analogues were prepared through palladium catalyzedoxa-Heck and aza-Heck reactions. Based on in vitro assays it was
possible to discover new compounds with both antitumoral and
antileishmanial activity. In particular, compound 8, a N-tosyl
aza-pterocarpan, represents an interesting model for the develop-
ment of new antineoplasic and antiparasite compounds.
4. Experimental
4.1. Pharmacology
4.1.1. Cell lines and cell culture
The tumor cell lines used in this work were HL-60 (promyelo-
cytic leukemia), K562 (chronic myelogenous leukemia), HCT-8
(colon carcinoma), MDA-MB 435 (melanoma) and SF-295 (gliobas-
toma) kindly provided by the National Cancer Institute (Bethesda,
MD, USA). Also, peripheral blood mononuclear cells (PBMC) were
tested, for chosen compounds. All cancer cells were maintained
in RPMI 1640 medium supplemented with 10% fetal bovine serum,
2 mM glutamine, 100 U/mL penicillin, 100 lg/mL streptomycin at
37 C with 5% CO2. Heparinized blood (from healthy, non-smoker
donors who had not taken any drug at least 15 days prior to sam-
pling) was collected and PBMC were isolated by a standard method
of density-gradient centrifugation over Ficoll-Hypaque. PBMCwere
washed and resuspended at a concentration of 3  105 cells/mL
and plated in a 96-well plate with RPMI 1640 medium supple-
mented with 20% fetal bovine serum, 2 mM glutamine, 100 U/mL
penicillin, 100 lg/mL streptomycin at 37 C with 5% CO2. Phyto-
hemagglutinin (3%) was added at the beginning of culture. After
24 h, tested compounds (0.1–25 lg/mL) dissolved in DMSO 1%
were added to each well and incubated for 72 h.4.1.2. Cytotoxicity assay
The cytotoxicity of all compounds was tested against ﬁve tumor
cell lines and PBMC using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-di-
phenyl-2H tetrazolium bromide (MTT) (Sigma Aldrich Co., St.
Louis, MO, USA) reduction assay. For all experiments, tumor cells
were plated in 96-well plates (105 cells/mL for adherent cells or
3  105 cells/mL for Leukemia). Tested Compounds (0.1–25 lg/mL)
dissolved in DMSO 1% were added to each well and incubated for
72 h. Control groups received the same amount of DMSO. After
72 h of incubation, the supernatant was replaced by fresh medium
containing MTT (0.5 mg/mL). Three hours later, the MTT formazan
product was dissolved in 150 lL of DMSO, and absorbance was
measured at 595 nm (DTX 880 Multimode Detector, Beckman
Coulter, Inc. Fullerton, CA, USA). Doxorubicin (0.01–5 lg/mL) was
used as positive control.
4.1.3. Antileishmanial activity
To evaluate the antileishmanial activity of pterocarpanquinon-
es, aza-pterocarpanquinones and analogues, L. amazonensis prom-
astigotes were maintained in ﬂasks at 26 C in Schneider’s
medium (Sigma–Aldrich Corp., St. Louis, MO, USA) supplemented
with 10% fetal bovine serum. Tests were performed in 96-well
plates for 72 h at 26 C with initial inoculums of 1.0  106/ml
and compound concentrations ranging from 0 to 20 lM. Parasite
viability was assessed by a dye-reduction assay employing
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT). After incubation, 22 lL of MTT solution (5 mg/mL) was
added per well, and then, the samples were incubated for an addi-
tional 2 h. Next, 80 lL of DMSO was added to each well and their
optical densities were measured at 570 nm in spectrometer.
To evaluate the effect of compounds on intracellular amastig-
otes, resident peritoneal macrophages of BALB/c were plated in
RPMI (Sigma–Aldrich, St. Louis, USA) at 2  106/mL (0.4 mL/well)
in Lab-Tek 8-chamber slides (Nunc, Roskilde, Denmark) and
C. D. Buarque et al. / Bioorg. Med. Chem. 19 (2011) 6885–6891 6889incubated at 37 C in 5% CO2 for 1 h. Stationary-phase L. amazonen-
sis promastigotes were added at a 3:1 parasite/macrophage ratio,
and the cultures were incubated for an additional 3 h. The resulting
monolayers were washed three times with pre-warmed
phosphate-buffered saline (PBS) to remove free parasites and
non-adherent cells, then 0.4 mL of compounds (at concentrations
ranging from 0 to 20 lM, each run in duplicate) was added, prior
to incubation for an additional 72 h. Next, the slides were stained
using an Instant Prov hematological dye system (Newprov, Curiti-
ba, Brazil) and then examined under light microscopy. The number
of intracellular amastigotes was determined by counting at least
100 macrophages per sample. To evaluate the toxicity of com-
pounds, cell line macrophages J774 (2106 in 200 lL) were incu-
bated with various concentrations of compounds for 72 h at
37 C/5% CO2. The effect on macrophage viability was quantiﬁed
using a MTT assay. Pentamidine isethionate was used as reference
in these experiments. All experiments were repeated at least three
times. Values of p <0.05 produced by Student’s t-test were consid-
ered statistically signiﬁcant. The IC50 and ED50 values were ob-
tained with Graphpad Prism 4 software.
4.2. Chemistry
Melting points were determined with a Thomas–Hoover appa-
ratus and are uncorrected. Column chromatography was per-
formed on silica gel 230–400 mesh (Aldrich). 1H NMR spectrum
was recorded on a Bruker Avance 400 (400.013 MHz) spectrometer
at room temperature. All J values are given in Hz. Chemical shifts
are expressed in parts per million downﬁeld shift from tetramethyl-
silane as an internal standard, and reported as position (dH) (relative
integral, multiplicity (s = singlet, d = doublet, dd = double doublet,
dt = double triplet, m = multiplet), coupling constant (J Hz) and
assignment. 13C NMR spectrum was recorded on a Bruker Avance
400 (100.003 MHz) spectrometer at room temperature with com-
plete proton decoupling. Data are expressed in parts per million
downﬁeld shift from tetramethylsilane as an internal standard
and reported as position (dC).
4.2.1. General procedure for the oxyarylation synthesis of
compounds type 1, compound 5 and 6
To a stirred solution of 9 (0.5 mmol), 13a (0,5 mmol) or 13b
(0.5 mmol) in acetone (10 mL), 2-iodophenols 10 (0.6 mmol), silver
carbonate (1.5 mmol) and Pd(OAc)2 (10 mol%) were added. This
experimental procedure was accomplished in presence
(20 mol %) or in absence of PPh3. The reaction mixture was reﬂuxed
for 8 h and ﬁltered in celite with ethyl acetate. The organic layer
was washed with brine, dried over anhydrous Na2SO4 and concen-
trated. The crude product was washed in n-hexane and puriﬁed by
ﬂash chromatography on silica.
4.2.1.1. Compound 1a. After column chromatography using
n-hexane/ethyl acetate (95:5) as eluant, this compound was
obtained as a yellow solid in 41% yield in presence of PPh3, and
in 40% in absence of PPh3, mp 145 C. 1H NMR (CDCl3) d (ppm)
8.21–8.10 (2H, m); 7.78–7.68 (2H, m); 7.30–7.18 (2H, m);
6.98–6.91 (2H, m); 5.66 (1H, d, J = 6.7 Hz); 4.59 (1H, dd, J = 11.1
and 5.0 Hz); 3.81 (1H, t, J = 11.1 Hz); 3.64–3.53 (m, 1H); 13C NMR
(CDCl3, 75 MHz) d (ppm) 183.25 (C); 179.28 (C); 158.73 (C);
157.01 (C); 134.54 (CH); 133.38 (CH); 130.58 (C); 130.57
(C); 129.58 (CH); 126.49 (CH); 126.42 (CH); 125.11 (C); 124.51
(CH); 121.23 (CH); 118.16 (C); 110.80 (CH); 72.32 (CH); 67.09
(CH2); 38.37 (CH); HRMS: [M+H]+ m/z calcd for C21H20O4,
305.0814 [M+H]+ m/z found: 305.0890.
4.2.1.2. Compound 1b. After column chromatography using
n-hexane/ethyl acetate (10:90) as eluant, this compound wasobtained as a yellow solid in 39% yield in absence of PPh3; mp
230–235 C; 1H NMR (400 MHz, CDCl3), d (ppm): 1H NMR (CDCl3)
d (ppm): 8.20 (1H, d, J = 7.5 Hz); 8.14 (1H, d, J = 7.4 Hz); 7.80–
7.72 (1H, m); 7.15 (1H, d, J = 8.1 Hz); 6.54 (1H, d, J = 2.0 Hz); 6.48
(1H, dd, J = 8.2 and 2.0 Hz); 5.66 (1H, d, J = 6.6 Hz); 4.55 (1H, dd,
J = 11.3 and 5.2 Hz); 3.78–3.73 (1H, m); 3.77 (3H, s); 3.53–3.47
(1H, m) 13C NMR (100 MHz, CDCl3) d (ppm): 183.4 (C); 179.5 (C);
161.5 (C); 160.3 (C); 157.2 (C); 134.7 (CH); 133.5 (CH); 132.1 (C);
130.8 (C); 126.7 (CH); 126.6 (CH); 124.8 (CH); 118.1 (C); 116.9
(C); 107.1 (CH); 97.5 (CH); 73.3 (CH); 67.5 (CH2); 55.5 (CH3);
37.9 (CH) LRMS (EI) m/z 334.
4.2.1.3. Compound 1c. After column chromatography using
n-hexane/ethyl acetate (10:90) as eluant, this compound was
obtained as a yellow solid in 22% yield in presence of PPh3 and
30% yield in absence of PPh3; mp 250–252 C; 1H NMR (400 MHz,
CDCl3), d (ppm): 8.21–8.13 (2H, m); 7.99 (1H, s); 7.97 (1H, d,
J = 8.6 Hz); 7.82–7.73 (2H, m); 6.95 (1H, d, J = 8.3 Hz); 5.77 (1H,
d, J = 6.8 Hz); 4.61 (1H, dd, J = 5.1 and 11.3 Hz); 3.89 (3H, s); 3.82
(1H, t, J = 11.0 Hz); 3.68–3.63 (1H, m); 13C NMR (75 MHz, CDCl3)
d (ppm): 183.2 (C); 179.1 (C); 166.4 (C); 162.7 (C); 157.2 (C);
134.7 (CH); 133.6 (CH); 132.5 (CH); 131.8 (C); 130.6 (C); 126.6
(CH); 126.6 (CH); 126.6 (CH); 126.4 (CH); 125.6 (C); 123.6 (C);
117.6 (C); 110.5 (CH); 73.5 (CH); 66.8 (CH2); 51.9 (CH3); 37.9
(CH); LRMS (EI) m/z 362.
4.2.1.4. Compound 1d. After column chromatography using
n-hexane/ethyl acetate (80:20) as eluant, this compound was
obtained as a yellow solid in <10% yield in presence of PPh3, an
in <10% in absence of PPh3, mp 250 C. 1H NMR (CDCl3) d
8.24–8.16 (m, 4H); 7.86–7.77 (m, 2H); 7.02 (d, 1H, J = 8.6 Hz);
5.90 (d, 1H, J = 6.3 Hz); 4.67 (d, 1H, J = 4.1 and 10.9 Hz); 3.90 (t,
1H, 10.8 Hz); 3.78–3.75 (m, 1H); 13C NMR (CDCl3, 75 MHz) d
179.0 (C); 164.2 (C); 157.4 (C); 142.6 (C); 134.9 (CH); 133.9 (CH);
131.8 (C); 130.7 (C); 127.2 (CH); 126.8 (CH); 126.8 (CH); 121.2
(CH); 117.3 (C); 110. 9 (CH); 74.8 (CH); 66.6 (CH2); 38.1 (CH). LRMS
(EI) m/z 349.
4.2.1.5. Compound 1e. After column chromatography using
n-hexane/ethyl acetate (70:30) as eluant, this compound was
obtained as a yellow solid in 12% yield in presence of PPh3, and in
16% in absence of PPh3, mp 160–165 C. 1H NMR (CDCl3) d (ppm):
9.82 (1H, s); 8.16 (1H, d, J = 7.6 Hz); 8.11 (1H, d, J = 7.4 Hz); 7.79–
7.71 (2H, m); 7.47 (1H, s); 7.37 (1H, s); 5,85 (1H, d, J = 6.8 Hz);
4.64 (1H, dd, J = 11.1 and 5.1 Hz); 3.91 (3H, s); 3.84 (1H, t,
J = 11.0 Hz); 3.75–3.70 (1H, m) 13C NMR (100 MHz, CDCl3) d
(ppm): 190.2 (CH); 190.1 (C); 182.8 (C); 179.1 (C); 157.2 (C); 153.0
(C); 145.7 (C); 134.8 (CH); 133.6 (CH); 131.9 (C); 130.6 (C); 127.3
(C); 126.7 (CH); 126.6 (CH); 120.3 (CH); 117.5 (C); 113.2 (CH);
74.4 (CH); 66.9 (CH2); 56.1 (CH3); 38.3 (CH). LRMS (EI)m/z 334.
4.2.1.6. Compound 5. After column chromatography using n-hex-
ane/ethyl acetate (5:95) as eluant, this compound was obtained as
a yellow solid 43% yield in absence of PPh3; mp 125–127 C; 1H
NMR (CDCl3, 400 MHz): d (ppm): 7.56 (1H, d, J = 7.4 Hz); 7,27
(2H, d, J = 8.3 Hz); 7.19 (1H, t, J = 7.6 Hz); 7,06 (1H, t, J = 7.3 Hz);
6.91–6.85 (1H, m); 5.54 (1H, d, J = 5.2 Hz); 4.31 (1H, d,
J = 5.7 Hz); 3.71–3.62 (1H, m); 13C NMR (CDCl3, 100 MHz): 163.1
(C); 159.6 (C); 135.2 (CH); 134.2 (CH); 133.4 (CH); 131.3 (C);
128.8 (CH); 125.8 (CH); 124.9 (CH); 124.3 (C); 121.5 (CH); 114.4
(CH); 81.8 (CH); 70.6 (CH2); 44.5 (CH).
4.2.1.7. Compound 6. After column chromatography using n-hex-
ane/ethyl acetate (5:95) as eluant, this compound was obtained as
a yellow solid in 50% in presence of PPh3 and 45% yield in absence
of PPh3; mp 40 C 1H NMR (200 MHz, CDCl3), d (ppm): 7.56–7.52
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5.63 (1H, d, J = 8.0 Hz), 3.71–3.70 (1H, m), 2.75–2.54 (2H, m), 2.96–
2.11 (1H, m), 1.87–1.71 (1H, m); 13C NMR (50 MHz, CDCl3), d
(ppm): 159.3 (C), 138.8 (C), 133.3 (C), 131.2 (C), 130.1 (CH),
128.3 (CH), 128.2 (CH), 126.6 (CH), 124.3 (CH), 120.5 (CH), 110.7
(CH), 109.5 (CH), 81.7 (CH), 40.9 (CH), 27.9 (CH2), 27.5 (CH2);
HRMS: [M+H]+m/z calcd for C16H14O 222.1123, [M+H]+m/z found:
222.1223.
4.2.2. General procedure for the oxyarylation: synthesis of
compounds type 3
To a stirred solution of 12 (0.5 mmol) in acetone (10 ml), 2-iodo-
phenols 10 (0.6 mmol), silver carbonate (1.5 mmol) and Pd(OAc)2
(10 mol %) were added. This experimental procedure was accom-
plished in presence (20 mol %) or in absence of PPh3. The reaction
mixture was reﬂuxed for 4 h and ﬁltered in celite with ethyl ace-
tate. The organic layer was washed with brine, dried over anhy-
drous Na2SO4 and concentrated. The crude product was washed
in n-hexane and puriﬁed by ﬂash chromatography on silica.
4.2.2.1. Compound 3a. After column chromatography using
n-hexane/ethyl acetate (95:5) as eluant, this compound was ob-
tained as a yellow oil in 50% yield in presence of PPh3, and in
45% in absence of PPh3 1H NMR (CDCl3, 400 MHz) d (ppm):
8.13–8.06 (2H, m); 7.54–7.39 (2H, m); 7.34–7.20 (2H, m); 6.97–
6.87 (2H, m); 5.98 (1H, d, J = 6.9 Hz); 4.39 (1H, dd, J = 11.0 and
4.8 Hz), 4.17 (3H, s); 3.98–3.82 (4H, m); 3.74–3.63 (1H, m).
13C NMR (CDCl3, 100 MHz) d (ppm): 159.6 (C); 153.4 (C); 144.4
(C); 138.8 (C); 129.7 (C); 129.2 (CH); 127.1 (C); 126.9 (CH); 124.5
(CH); 124.1 (CH); 123.5 (C); 122.5 (CH); 121.7 (CH); 120.9 (CH);
114.8 (C); 110.2 (CH); 75.0 (CH3); 66.8 (CH2); 61.2 (CH3); 40.3 (CH).
HRMS: [M+H]+ m/z calcd for C19H12O4: 335.1283, [M+H]+ m/z
found: 335.0999.
4.2.2.2. Compound 3b. After column chromatography using
n-hexane/ethyl acetate (90:10) as eluant, this compound was
obtained as a yellow solid in 26% yield in presence of PPh3, and
in 26% in absence of PPh3; mp 210 C; 1H NMR (400 MHz, CDCl3):
d (ppm) = 8.30–8.06 (4H, m), 7.52 (1H, t, J = 7.7 Hz); 7.44 (1H, t,
J = 8.1 Hz); 6.88 (1H, d, J = 8.8 Hz); 6.27 (1H, d, J = 7.8 Hz); 4.39
(1H, dd, J = 4.7 and 11.3 Hz); 4.16 (3H, s); 4.04 (1H, dd, J = 8.2
and 11.2 Hz); 3.95 (3H, s); 3.91–3.88 (1H, m); 13C NMR
(100 MHz, CDCl3), d (ppm): 164.7 (C); 153.1 (C); 144.0 (C); 142.1
(C); 138.8 (C) 129.7 (C); 128.4 (C); 127.3 (CH); 126.6 (CH); 124.5
(CH); 123.4 (C); 122.4 (CH); 121.7 (CH); 121.0 (CH); 113.4 (C);
109.8 (CH); 77.2 (CH); 66.6 (CH2); 64.0 (CH3); 61.9 (CH3); 39.7
(CH); LRMS (EI) m/z 379.
4.2.2.3. Compound 3c. After column chromatography using
n-hexane/ethyl acetate (90:10) as eluant, this compound was
obtained as a yellow solid in 39% yield in presence of PPh3, and
in 43% in absence of PPh3; mp 145 C; 1H NMR (400 MHz, CDCl3):
d (ppm) = 8.12–8.01 (2H, m); 8.02 (1H, s); 7.96 (1H, d, J = 8.4 Hz);
7.51 (1H, t, J = 7.2 Hz); 7.42 (1H, t, J = 7.8 Hz); 6.88 (1H, d,
J = 8.4 Hz); 4.39 (1H, dd, J = 11.2 and 4.8 Hz); 4.17 (3H, s); 3.95
(3H, s); 3.90–3.87 (4H, m); 3.81–3.76 (1H, m); 13C NMR
(100 MHz, CDCl3), d (ppm): 166.8 (C); 163.6 (C); 153.3 (C); 144.3
(C); 138.8 (C); 132.2 (CH); 129.7 (C); 127.5 (C); 127.3 (CH); 126.6
(CH); 124.4 (CH); 123.5 (C); 123.3 (C); 122.5 (CH); 121.7 (CH);
114.12 (C); 109.9 (CH); 76.2 (CH); 66.7 (CH2); 64.1 (CH3); 61.5
(CH3); 52.0 (CH3); 39.8 (CH); LRMS (EI) m/z 392.
4.2.3. Azaarylation reactions: synthesis of 4, 7 and 8
To a stirred solution of 12 (0.5 mmol), 13a (0.5 mmol) or 13b
(0.5 mmol) in acetone (10 mL), tosyl-2-iodoaniline 12 (0.75 mmol),silver carbonate (1.5 mmol) and Pd(OAc)2 (10 mol %) were added.
This experimental procedure was accomplished in presence
(20 mol %) or in absence of PPh3. The reaction mixture was reﬂuxed
for 8 h and ﬁltered in celite with ethyl acetate. The organic layer
was washed with brine, dried over anhydrous Na2SO4 and
concentrated. The crude product was washed in n-hexane and
puriﬁed by ﬂash chromatography on silica.
4.2.3.1. Compound 4. After column chromatography using n-hex-
ane/ethylacetate (5:95) as eluant, this compound was obtained as a
yellow solid in 45% yield in absence of PPh3; mp: 50–55 C 1H NMR
(CDCl3, 400 MHz): d (ppm): 8.08 (1H, d, J = 8.4 Hz); 7.95 (1H, d,
J = 8.4 Hz); 7.51 (1H, d, J = 7.8 Hz); 7.51–7.46 (3H, m); 7.37–7.33
(1H, m); 7.24–7.10 (5H, m); 5.92 (1H, d, J = 7.9 Hz); 4.60 (1H, dd,
J = 11.8 and 2.0 Hz); 4.21 (3H, s); 4.07 (1H, dd, J = 11.8 and
2.0 Hz); 3.0 (3H, s); 2.94 (1H, d, J = 7.9 Hz); 2.36 (3H, s); 13C NMR
(CDCl3, 100 MHz): d (ppm): 153.6 (C); 145.4 (C); 144.0 (C); 143.1
(C); 138.1 (C); 135.2 (C); 134.5 (C); 129.3 (CH); 129.3 (CH);
129.01 (C); 128.3 (CH); 127.7 (CH); 127.7 (CH); 126.8 (CH);
126.5 (CH); 123.9 (CH); 123.7 (CH); 123.6 (C); 122.8 (CH); 121.5
(CH); 121.2 (CH); 114.8 (C); 63.9 (CH2); 63.1 (CH3); 61.0 (CH);
59.4 (CH3); 40.8 (CH); 21.5 (CH3) LRMS (EI) m/z 332.
4.2.3.2. Compound 7. After column chromatography using n-hex-
ane/ethyl acetate (5:95) as eluant, this compound was obtained as
a white solid in 29% yield in absence of PPh3; mp 55–60 C 1H NMR
(CDCl3, 400 MHz): d (ppm): 7.86 (1H, d, J = 7.6 Hz); 7.59 (1H, m);
7.51 (2H, d, J = 8.1 Hz); 7.20–7.17 (2H, m); 7.14–7.11 (3H, m);
7.10 (1H, t, J = 7.7 Hz); 7.01 (1H, t, J = 7.4 Hz); 6.66 (1H, d,
J = 8.2 Hz); 5.47 (1H, d, J = 8.6 Hz); 4.48 (1H, d, J = 12.0 Hz); 4.15
(1H, dt, J = 12.0 and 5.8 Hz); 3.04 (1H, d, J = 8.7 Hz); 2.37 (3H,s)
13C NMR (CDCl3, 100 MHz): d (ppm: 155.6 (C); 144.0 (C); 141.9
(C); 135.4 (C); 133.2 (C); 131.3 (CH); 129.7 (CH); 129.1 (CH);
128.6 (CH); 127.0 (CH); 125.9 (CH); 123.4 (CH); 122.1 (CH);
121.3 (C); 120.1 (CH); 116.9 (CH); 64.1 (CH2); 59.8 (CH); 40.5
(CH); 21.5 (CH3). LRMS (EI) m/z 349.
4.2.3.3. Compound 8. After column chromatography using n-hex-
ane/ethylacetate (5:95) as eluant, this compound was obtained as a
yellow solid in 45% yield in absence of PPh3; mp: 160–165 C 1H
NMR (CDCl3, 400 MHz):d (ppm): 8.0 (1H, d, J = 7.8 Hz); 7.61 (1H,
d, J = 7.9 Hz); 7.51 (1H, d, J = 8.1 Hz); 7.29–7.09 (7H, m); 7.04
(1H, d, J = 7.0 Hz); 6.93 (1H, d, J = 7.5 Hz); 5.42 (1H, d, J = 8.5 Hz);
3.13–3.11 (1H, m); 2.54–2.45 (2H, m); 2.37 (3H, m); 2.13–2.09
(1H, m); 2.06–1.98(1H,m); 13C NMR (CDCl3,100 MHz): d (ppm):
143.8 (C);142.1(C); 137.6 (C);136.2 (C); 135.6 (C); 134.4 (C); 30.5
(CH); 129.6 (CH); 129.6 (CH); 127.9 (CH); 127.8 (CH); 127.3(CH);
127.1(CH); 127.1 (CH); 126.8 (CH); 125.7 (CH); 123.4 (CH); 119.9
(CH); 64.0 (CH); 39.5 (CH); 24.8 (CH2); 23.6 (CH2); 21.5 (CH3).
LRMS (EI) m/z 220.
4.2.4. Procedure for the reaction for substance 2 and alternative
procedure for 1a, 1c and 1d
To a stirred solution of substances 3a, 3c, 3d and 4 (0.12 mmol)
in acetonitrile, cerium nitrate ammonium (CAN) (3 equiv;
0.036 mmol) in 0.25 mL of water was added slowly and the reac-
tion mixture was stirred for 15 min at room temperature. After
that, the reaction mixture was extracted with ethyl acetate and
the organic layer was washed with 50% aq NaHCO3 solution, dried
over anhydrous Na2SO4 and concentrated to obtain the crude prod-
ucts in 77% yield (1a), 85% yield (1c), 75% yield (1d) and 74% yield
(2).
4.2.4.1. Compound 2. Crude product was obtained in pure form
74% yield. 1H NMR (CDCl3, 400 MHz): d (ppm): 8.22 (1H, dd,
J = 7.7 and 1.0 Hz); 8.06 (1H, dd, J = 7.7 and 1.0 Hz); 7.79–7.75
C. D. Buarque et al. / Bioorg. Med. Chem. 19 (2011) 6885–6891 6891(1H, m); 7.70 (1H, dd, J = 7.6 and 1.3 Hz); 7.66 (1H, d, J = 8.3 Hz),
7.58 (1H, d, J = 8.1 Hz) 7.31–7.27 (2H, m); 7.22–7.14 (4H, m);
5.65 (1H, d, J = 7.1 Hz); 4.44 (1H, dd, J = 12.1 and 5.1 Hz); 4.25
(1H, dd, J = 12.1 and 3.3 Hz); 3.12–3.08 (1H, m); 2.40 (3H, s) 13C
NMR (CDCl3, 400 MHz): d (ppm): 182.7(C); 179.2(C); 156.5(C);
144.2 (C); 144.1 (C); 142.4 (C); 135.1 (C); 134.5 (CH); 133.1 (CH);
132.5 (C); 131.5(C); 130.5 (C); 129.5 (CH); 129.5 (CH); 128.9
(CH); 127.7 (CH); 127.7 (CH); 126.8 (CH); 126.2 (CH); 125.8
(CH); 123.9 (CH); 120.1 (CH); 65.5 (CH2); 56.5 (CH); 39.0 (CH);
21.6 (CH3). LRMS (EI) m/z 302.
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